Rx-101005(Rx-101005) - 药物靶点：Folate_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

Folate

作用机制

叶酸抑制剂

治疗领域

感染

在研适应症-

非在研适应症

细菌感染真菌病

原研机构

Trius Therapeutics, Inc.

在研机构-

非在研机构

Trius Therapeutics, Inc.

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 Rx-101005 相关的临床结果

登录后查看更多信息

100 项与 Rx-101005 相关的转化医学

登录后查看更多信息

100 项与 Rx-101005 相关的专利（医药）

登录后查看更多信息

1

项与 Rx-101005 相关的文献（医药）

2010-11-01·IDrugs : the investigational drugs journal

Interscience Conference on Antimicrobial Agents and Chemotherapy - 50th Annual Meeting - Research on Promising New Agents: Part 1.

作者: Walker, Karen

The 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held in Boston, included topics covering new therapeutic developments in the field of infectious disease. This conference report highlights selected presentations on research with novel antimicrobial agents. Investigational drugs discussed include the dicationic porphyrin derivative XF-73 (Destiny Pharma), the tetracycline analog TP-434 (Tetraphase Pharmaceuticals), an elongation factor Tu inhibitor (Novartis Institutes for BioMedical Research), the dihydrofolate reductase inhibitor Rx-101005 (Trius Therapeutics), SII RMab, a fully human mAb to rabies glycoprotein (Massachusetts Biologic Laboratories/Serum Institute of India), the oral lipopeptide CB-183315 (Cubist Pharmaceuticals) for the treatment of Clostridium difficile-associated diarrhea, the phosphatidylcholine-specific phospholipase C (PC-PLC) inhibitor LMV-601 (Lumavita), and DS-003 (International Partnership for Microbicides), a small-molecule Gp120 inhibitor.

100 项与 Rx-101005 相关的药物交易

登录后查看更多信息